{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:57:20Z","timestamp":1793501840218,"version":"4.5.0"},"reference-count":198,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015477","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:16:22Z","timestamp":1670372182000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Efficacy and safety of COVID-19 vaccines"],"prefix":"10.1002","volume":"2023","author":[{"given":"Carolina","family":"Gra\u00f1a","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Evrenoglou","sequence":"additional","affiliation":[{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jarde","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Minozzi","sequence":"additional","affiliation":[{"name":"Cochrane Review Group on Drugs and Alcohol; Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Buckley","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Probyn","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Henschke","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba","family":"Assi","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Menon","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Marti","sequence":"additional","affiliation":[{"name":"Department of Immunization, Vaccines and Biologicals; World Health Organization; Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Devane","sequence":"additional","affiliation":[{"name":"Evidence Synthesis Ireland, Cochrane Ireland and HRB-Trials Methodology Research Network; National University of Ireland; Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mallon","sequence":"additional","affiliation":[{"name":"UCD Centre for Experimental Pathogen Host Research and UCD School of Medicine; University College Dublin; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Daniel","family":"Lelievre","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital; Vaccine Research Institute, Universit\u00e9 Paris Est Cr\u00e9teil; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Askie","sequence":"additional","affiliation":[{"name":"Quality Assurance Norms and Standards Department; World Health Organization; Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kredo","sequence":"additional","affiliation":[{"name":"Cochrane South Africa; South African Medical Research Council; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ferrand","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricia","family":"Davidson","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Riveros","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tovey","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg J","family":"Meerpohl","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine, Medical Center & Faculty of Medicine; University of Freiburg; Freiburg Germany"},{"name":"Cochrane Germany; Cochrane Germany Foundation; Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Grasselli","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation; University of Milan; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Rada","sequence":"additional","affiliation":[{"name":"Epistemonikos Foundation; Santiago Chile"},{"name":"UC Evidence Center, Cochrane Chile Associated Center; Pontificia Universidad Cat\u00f3lica de Chile; Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbj\u00f8rn","family":"Hr\u00f3bjartsson","sequence":"additional","affiliation":[{"name":"Centre for Evidence Based Medicine Odense (CEBMO) and Cochrane Denmark; University of Southern Denmark; Odense Denmark"},{"name":"Open Patient data Explorative Network (OPEN); Odense University Hospital; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chaimani","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boutron","sequence":"additional","affiliation":[{"name":"Cochrane France; Paris France"},{"name":"Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE; Universit\u00e9 de Paris; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"issue":"24","key":"10.1002\/14651858.CD015477-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015477-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijid.2021.10.030","article-title":"Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1\/2 trial","volume":"114","author":"Asano","year":"2022","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Bonelli M Mrak D Tobudic S Sieghart D Koblischke M Mandl P Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial medRxiv 2021 [Preprint] 10.1101\/2021.09.05.21263125","DOI":"10.1101\/2021.09.05.21263125"},{"key":"10.1002\/14651858.CD015477-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Bueno SM Abarca K Gonz\u00e1lez PA G\u00e1lvez NM Soto JA Duarte LF Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial medRxiv 2021 [Preprint] 10.1101\/2021.03.31.21254494","DOI":"10.1101\/2021.03.31.21254494"},{"key":"10.1002\/14651858.CD015477-BIB0006|cit6","unstructured":"Bueno SM Abarca K Gonz\u00e1lez PA G\u00e1lvez NM Soto JA Duarte LF Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile Clinical Infectious Diseases 10.1093\/cid\/ciab823"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1038\/s41467-021-25982-w","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil","volume":"12","author":"Clemens","year":"2021","journal-title":"Nature Communications"},{"key":"10.1002\/14651858.CD015477-BIB0008|cit8","unstructured":"Dunkle LM Kotloff KL Gay CL \u00c1\u00f1ez G Adelglass JM Barrat Hern\u00e1ndez AQ Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico medRxiv 2021 [Preprint] 10.1101\/2021.10.05.21264567"},{"key":"10.1002\/14651858.CD015477-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Ella R Vadrevu KM Jogdand H Prasad S Reddy S Sarangi V A Phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152 medRxiv 2020 [Preprint] 10.1101\/2020.12.11.20210419","DOI":"10.2139\/ssrn.3747047"},{"issue":"5","key":"10.1002\/14651858.CD015477-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Ella R Reddy S Blackwelder W Potdar V Yadav P Sarangi V Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomized, controlled phase 3 trial medRxiv 2021 [Preprint] 10.1101\/2021.06.30.21259439","DOI":"10.1101\/2021.06.30.21259439"},{"issue":"5","key":"10.1002\/14651858.CD015477-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD015477-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0014|cit14","unstructured":"Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; FDA Briefing Document: Moderna COVID-19 vaccine www.fda.gov\/media\/144434\/download"},{"issue":"10282","key":"10.1002\/14651858.CD015477-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomized controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"issue":"44","key":"10.1002\/14651858.CD015477-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","article-title":"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359\u00a0years: an interim analysis in Indonesia","volume":"39","author":"Fadlyana","year":"2021","journal-title":"Vaccine"},{"issue":"25","key":"10.1002\/14651858.CD015477-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015477-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"e1003769","DOI":"10.1371\/journal.pmed.1003769","article-title":"Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial","volume":"18","author":"Formica","year":"2021","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Formica N Mallory R Albert G Robinson M Plested JS Cho I Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults medRxiv 2021 [Preprint] 10.1101\/2021.02.26.21252482","DOI":"10.1101\/2021.02.26.21252482"},{"issue":"3","key":"10.1002\/14651858.CD015477-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Klein","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"101010","DOI":"10.1016\/j.eclinm.2021.101010","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1\/2 trial","volume":"38","author":"Guo","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"13","key":"10.1002\/14651858.CD015477-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD015477-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomized, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infectious Diseases"},{"issue":"13","key":"10.1002\/14651858.CD015477-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Heath PT Galiza EP Baxter DN Boffito M Browne D Burns F Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1.7 variant medRxiv 2021 [Preprint]","DOI":"10.1056\/NEJMoa2107659"},{"key":"10.1002\/14651858.CD015477-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"New England Journal of Medicine\u00a0"},{"key":"10.1002\/14651858.CD015477-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Kremsner PG Ahuad Guerrero RA Arana-Arri E Aroca Martinez GJ Bonten M Chandler R Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b\/3, randomized, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America SSRN 2021 [Preprint] 10.2139\/ssrn.3911826","DOI":"10.2139\/ssrn.3911826"},{"key":"10.1002\/14651858.CD015477-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"101218","DOI":"10.1016\/j.eclinm.2021.101218","article-title":"A phase 2\/3, observer-blind, randomized, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 vaccine) in adults in India","volume":"42","author":"Kulkarni","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1002\/14651858.CD015477-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Li J Hou L Guo X Jin P Wu S Zhu J Heterologous prime-boost immunization with CoronaVac and Convidecia medRxiv 2021 [Preprint] 10.1101\/2021.09.03.21263062","DOI":"10.1101\/2021.09.03.21263062"},{"issue":"10303","key":"10.1002\/14651858.CD015477-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomized, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0031|cit31","unstructured":"Liu X Shaw RH Stuart AS Greenland M Aley PK Andrews NJ Safety and immunogenicity report from the Com-COV Study \u2013 a single-blind randomized non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine SSRN 2021 [Preprint] 10.2139\/ssrn.3874014"},{"issue":"10275","key":"10.1002\/14651858.CD015477-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD015477-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomized, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"issue":"20","key":"10.1002\/14651858.CD015477-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0035|cit35","unstructured":"Mok C Cheng S Chen C Yiu K Chan TO Lai KC A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac medRxiv 2021 [Preprint] 10.1101\/2021.11.02.21265843"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1186\/s13063-020-04775-4","article-title":"Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac \u2013 PROFISCOV: a structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Palacios","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015477-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Sablerolles RS Rietdijk WJ Goorhuis A Postma DF Visser LG Geers D Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV2.S priming medRxiv 2021 [Preprint] 10.1101\/2021.10.18.21264979","DOI":"10.1101\/2021.10.18.21264979"},{"key":"10.1002\/14651858.CD015477-BIB0038|cit38","unstructured":"Vaccines and related biological products Advisory Committee Meeting; February 26, 2021; FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19 www.fda.gov\/media\/146217\/download"},{"issue":"19","key":"10.1002\/14651858.CD015477-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a Phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Sadoff J Le Gars M Shukarev G Heerwegh D Truyers C de Groot AM Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial medRxiv 2020 [Preprint] 10.1101\/2020.09.23.20199604","DOI":"10.1101\/2020.09.23.20199604"},{"issue":"23","key":"10.1002\/14651858.CD015477-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD015477-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Shinde","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Shinde V Bhikha S Hoosain Z Archary M Bhorat Q Fairlie L Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant medRxiv 2021 [Preprint] 10.1101\/2021.02.25.21252477","DOI":"10.1056\/NEJMoa2103055"},{"issue":"10296","key":"10.1002\/14651858.CD015477-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0045|cit45","unstructured":"Vaccines and related biological products Advisory Committee Meeting; December 10, 2020; FDA briefing document: Pfizer-BioNTech COVID-19 vaccine www.fda.gov\/media\/144245\/download"},{"issue":"27","key":"10.1002\/14651858.CD015477-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD015477-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0048|cit48","unstructured":"Thomas SJ Kitchin N Absalon J Gurtman A Lockhart S Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine medRxiv 2021 [Preprint] 10.1101\/2021.07.28.21261159"},{"key":"10.1002\/14651858.CD015477-BIB0049|cit49","unstructured":"Toledo-Romani ME Garcia-Carmenate M Silva-Valenzuela C Baldoquin-Rodriguez W Mart\u00ednez-P\u00e9rez M Rodr\u00edguez-Gonz\u00e1lez M Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomized, placebo-controlled phase 3 clinical trial medRxiv 2021 [Preprint] 10.1101\/2021.10.31.21265703"},{"issue":"10249","key":"10.1002\/14651858.CD015477-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomized controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"10269","key":"10.1002\/14651858.CD015477-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Walsh EE Frenck R Falsey AR Kitchin N Absalon J Gurtman A RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study medRxiv 2020 [Preprint] 10.1101\/2020.08.17.20176651","DOI":"10.1101\/2020.08.17.20176651"},{"issue":"25","key":"10.1002\/14651858.CD015477-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015477-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD015477-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD015477-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomized, double-blind, controlled, phase 1\/2 trial","volume":"22","author":"Xia","year":"2021","journal-title":"Lancet Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD015477-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Baden LR El Sahly HM Essink B Follmann D Neuzil KM August A Covid-19 in the phase 3 trial of mRNA-1273 during the Delta-variant surge medRxiv 2021 [Preprint] 10.1101\/2021.09.17.21263624","DOI":"10.1101\/2021.09.17.21263624"},{"issue":"2","key":"10.1002\/14651858.CD015477-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015477-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nature Medicine"},{"issue":"10304","key":"10.1002\/14651858.CD015477-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","article-title":"Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomized controlled trials (COV001 and COV002)","volume":"398","author":"Flaxman","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"100989","DOI":"10.1016\/j.eclinm.2021.100989","article-title":"Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC-COV1901) adjuvanted with CpG 1018 and aluminum hydroxide in healthy adults: a phase 1, dose-escalation study","volume":"38","author":"Hsieh","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1002\/14651858.CD015477-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"JC50","DOI":"10.7326\/ACPJ202105180-050","article-title":"In South Africa, a 2-dose Oxford\/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)","volume":"174","author":"Irfan","year":"2021","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Lazarus R Baos S Cappel-Porter H Carson-Stevens A Clout M Culliford L The safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults: a phase IV, multicentre randomized controlled trial with blinding (ComFluCOV) SSRN 2021 [Preprint] 10.2139\/ssrn.3931758","DOI":"10.2139\/ssrn.3931758"},{"key":"10.1002\/14651858.CD015477-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Patamatamkul S Thammawat S Buranrat B Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac medRxiv 2021 [Preprint] 10.1101\/2021.09.25.21264099","DOI":"10.1101\/2021.09.25.21264099"},{"issue":"10","key":"10.1002\/14651858.CD015477-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.vaccine.2021.01.004","article-title":"Phase III: randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49\u00a0years of age","volume":"39","author":"Ward","year":"2021","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015477-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Wu K Choi A Koch M Ma LZ Hill A Nunna N Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster medRxiv 2021 [Preprint] 10.1101\/2021.05.05.21256716","DOI":"10.1101\/2021.05.05.21256716"},{"issue":"6","key":"10.1002\/14651858.CD015477-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/vaccines9060675","article-title":"Evaluation of SARS-CoV-2 spike protein antibody titers in cord blood after COVID-19 vaccination during pregnancy in Polish healthcare workers: preliminary results","volume":"9","author":"Zdanowski","year":"2021","journal-title":"Vaccines"},{"issue":"12","key":"10.1002\/14651858.CD015477-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2020.16866","article-title":"COVID-19 and mRNA vaccines \u2013 first large test for a new approach","volume":"324","author":"Abbasi","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015477-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"100153","DOI":"10.1016\/j.jvacx.2022.100153","article-title":"Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers","volume":"10","author":"Angkasekwinai","year":"2022","journal-title":"Vaccine X"},{"key":"10.1002\/14651858.CD015477-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"n436","DOI":"10.1136\/bmj.n436","article-title":"Severe Covid-19 pneumonia: pathogenesis and clinical management","volume":"372","author":"Attaway","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD015477-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evidence-Based Mental Health"},{"issue":"10295","key":"10.1002\/14651858.CD015477-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD015477-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/M20-5261","article-title":"The COVID-NMA Project: building an evidence ecosystem for the COVID-19 pandemic","volume":"173","author":"Boutron","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD015477-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013769","article-title":"Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review","author":"Boutron","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10288","key":"10.1002\/14651858.CD015477-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(21)00899-0","article-title":"Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial","volume":"397","author":"Bucci","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0079|cit79","unstructured":"Bueno SM Abarca K Gonz\u00e1lez PA G\u00e1lvez NM Soto JA Duarte LF Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial medRxiv"},{"issue":"6","key":"10.1002\/14651858.CD015477-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1007\/s11192-021-03900-7","article-title":"Day-to-day discovery of preprint-publication links","volume":"126","author":"Cabanac","year":"2021","journal-title":"Scientometrics"},{"key":"10.1002\/14651858.CD015477-BIB0081|cit81","unstructured":"Castagneto Gissey L Panunzi S Maltese S Russo MF Angelini G De Gaetano A Living systematic meta-analysis of COVID-19 vaccines and dose allocation strategies SSRN 10.2139\/ssrn.3827806"},{"key":"10.1002\/14651858.CD015477-BIB0082|cit82","unstructured":"Centers for Disease Control and Prevention Understanding mRNA COVID-19 vaccines www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/mrna.html"},{"issue":"10","key":"10.1002\/14651858.CD015477-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8\u00a0","author":"Chaimani","year":"2013","journal-title":"PLOS One\u00a0"},{"issue":"4","key":"10.1002\/14651858.CD015477-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the Network Graphs Package","volume":"15","author":"Chaimani","year":"2015","journal-title":"Stata Journal"},{"key":"10.1002\/14651858.CD015477-BIB0085|cit85","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"10","key":"10.1002\/14651858.CD015477-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(21)00200-0","article-title":"Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"21","author":"Chappell","year":"2021","journal-title":"Lancet Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD015477-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"e3949","DOI":"10.1093\/cid\/ciaa1703","article-title":"Randomized, double-blinded, placebo-controlled Phase 2 trial of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in healthy adults","volume":"73","author":"Che","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"20","key":"10.1002\/14651858.CD015477-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD015477-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/S1473-3099(21)00263-2","article-title":"Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities","volume":"21","author":"Dal-R\u00e9","year":"2021","journal-title":"Lancet Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD015477-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41591-021-01338-1","article-title":"Being fair to participants in placebo-controlled COVID-19 vaccine trials","volume":"27","author":"Dal-R\u00e9","year":"2021","journal-title":"Nature Medicine"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD015477-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1093\/infdis\/jiw352","article-title":"Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus","volume":"214","author":"DeZure","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"7-8","key":"10.1002\/14651858.CD015477-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1002\/14651858.CD015477-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015477-BIB0095|cit95","unstructured":"Ella R Reddy S Jogdand H Sarangi V Ganneru B Prasad S Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report medRxiv 10.1101\/2020.12.21.20248643"},{"issue":"7","key":"10.1002\/14651858.CD015477-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomized, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomized phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/bs.aivir.2016.08.003","article-title":"Molecular basis of coronavirus virulence and vaccine development","volume":"96","author":"Enjuanes","year":"2016","journal-title":"Advances in Virus Research"},{"key":"10.1002\/14651858.CD015477-BIB0098|cit98","unstructured":"Epistemonikos L\u00b7OVE COVID-19 platform Available at app.iloveevidence.com\/loves\/5e6fdb9669c00e4ac072701d?utm=ile"},{"key":"10.1002\/14651858.CD015477-BIB0099|cit99","unstructured":"Development and licensure of vaccines to prevent COVID-19. Guidance for industry; June 2020 www.fda.gov\/media\/139638\/download"},{"key":"10.1002\/14651858.CD015477-BIB0100|cit100","unstructured":"FDA Briefing Document Moderna COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting December 17, 2020 www.fda.gov\/media\/144434\/download"},{"key":"10.1002\/14651858.CD015477-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020 www.fda.gov\/media\/144245\/download","DOI":"10.47287\/cen-09931-buscon1"},{"key":"10.1002\/14651858.CD015477-BIB0102|cit102","unstructured":"FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021 www.fda.gov\/media\/146217\/download"},{"issue":"10328","key":"10.1002\/14651858.CD015477-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0104|cit104","unstructured":"Feng Y Chen J Yao T Chang Y Li X Xing R Safety and Immunogenicity of Inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial medRxiv 10.1101\/2021.08.06.21261696"},{"key":"10.1002\/14651858.CD015477-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0106|cit106","unstructured":"Formica N Mallory R Albert G Robinson M Plested JS Cho I the 2019nCoV-101 Study Group Evaluation of a SARS-CoV-2 vaccine NVX-CoV2373 in younger and older adults medRxiv 10.1101\/2021.02.26.21252482"},{"issue":"Pt B","key":"10.1002\/14651858.CD015477-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"New Biotechnology"},{"key":"10.1002\/14651858.CD015477-BIB0108|cit108","unstructured":"What are viral vector-based vaccines and how could they be used against COVID-19? www.gavi.org\/vaccineswork\/what-are-viral-vector-based-vaccines-and-how-could-they-be-used-against-covid-19"},{"key":"10.1002\/14651858.CD015477-BIB0109|cit109","unstructured":"Gobeil P Pillet S S\u00e9guin A Boulay I Mahmood A Vinh DC Interim report of a Phase 2 randomized trial of a plant-produced virus-like particle vaccine for Covid-19 in healthy adults aged 18-64 and older adults aged 65 and older medRxiv 10.1101\/2021.05.14.21257248"},{"issue":"9","key":"10.1002\/14651858.CD015477-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1473-3099(21)00147-X","article-title":"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study","volume":"21","author":"Goepfert","year":"2021","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0111|cit111","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"12","key":"10.1002\/14651858.CD015477-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence \u2013 imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"28","key":"10.1002\/14651858.CD015477-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2100563","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100563","article-title":"Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021","volume":"26","author":"Harder","year":"2021","journal-title":"Eurosurveillance"},{"issue":"11","key":"10.1002\/14651858.CD015477-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/vaccines9111305","article-title":"Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review","volume":"9","author":"Hayawi","year":"2021","journal-title":"Vaccines"},{"key":"10.1002\/14651858.CD015477-BIB0115|cit115","unstructured":"Heath PT Galiza EP Baxter DN Boffito M Browne D Burns F Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.1.7 variant medRxiv 10.1101\/2021.05.13.21256639"},{"key":"10.1002\/14651858.CD015477-BIB0116|cit116","unstructured":"Higdon MM Wahl B Jones CB Rosen JG Truelove SA Baidya A A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease medRxiv 10.1101\/2021.09.17.21263549"},{"key":"10.1002\/14651858.CD015477-BIB0117|cit117","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"11","key":"10.1002\/14651858.CD015477-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines \u2013 how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD015477-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE Working Group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015477-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"k3802","DOI":"10.1136\/bmj.k3802","article-title":"Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews","volume":"362","author":"Kirkham","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"e0260733","DOI":"10.1371\/journal.pone.0260733","article-title":"Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials","volume":"17","author":"Korang","year":"2022","journal-title":"PLOS One"},{"issue":"5","key":"10.1002\/14651858.CD015477-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/jmv.27568","article-title":"The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: a systematic review and meta-analysis","volume":"94","author":"Kow","year":"2022","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD015477-BIB0123|cit123","unstructured":"Lazarus R Taucher C Brown C \u010corbic I Danon L Dubischar K Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 \/2 clinical trial medRxiv 10.1101\/2021.08.13.21262021"},{"issue":"6","key":"10.1002\/14651858.CD015477-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0125|cit125","unstructured":"Li M Yang J Wang L Wu Q Wu Z Zheng W A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomized, double-blind, placebo-controlled, phase 1\/2 clinical trial medRxiv 10.1101\/2021.08.03.21261544"},{"key":"10.1002\/14651858.CD015477-BIB0126|cit126","unstructured":"Liu X Shaw RH Stuart AS Greenland M Dinesh T Provstgaard-Morys S Safety and immunogenicity report from the com-COV study \u2013 a single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine SSRN"},{"key":"10.1002\/14651858.CD015477-BIB0127|cit127","unstructured":"Low JG de Alwis R Chen S Kalimuddin S Leong YA Mah TK A phase 1\/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults medRxiv 10.1101\/2021.07.01.21259831"},{"issue":"10","key":"10.1002\/14651858.CD015477-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/vaccines9101102","article-title":"Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review","volume":"9","author":"Lv","year":"2021","journal-title":"Vaccines"},{"key":"10.1002\/14651858.CD015477-BIB0129|cit129","unstructured":"Madhi SA Koen AL Fairlie L Cutland CL Baillie V Padayachee SD ChAdOx1 nCoV-19 (AZD1222) vaccine in people living with and without HIV Research Square 10.21203\/rs.3.rs-322470\/v1"},{"issue":"5","key":"10.1002\/14651858.CD015477-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"e12529","DOI":"10.1002\/rth2.12529","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis (VITT)","volume":"5","author":"Makris","year":"2021","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD015477-BIB0131|cit131","unstructured":"Tebas P Agnes J Giffear M Kraynyak KA Blackwood E Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure medRxiv 10.1101\/2021.05.07.21256652"},{"issue":"8","key":"10.1002\/14651858.CD015477-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"30","key":"10.1002\/14651858.CD015477-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1002\/sim.6321","article-title":"A selection model for accounting for publication bias in a full network meta-analysis","volume":"33","author":"Mavridis","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41392-021-00692-3","article-title":"Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials","volume":"6","author":"Meng","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1-2","key":"10.1002\/14651858.CD015477-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.febslet.2004.09.009","article-title":"Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system","volume":"576","author":"Mortola","year":"2004","journal-title":"FEBS Letters"},{"issue":"7830","key":"10.1002\/14651858.CD015477-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1002\/14651858.CD015477-BIB0137|cit137","unstructured":"Nguyen TP Do Q Phan LT Dinh DV Khong H Hoang LV Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine medRxiv 10.1101\/2021.07.22.21260942"},{"issue":"4","key":"10.1002\/14651858.CD015477-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17\u00a0","author":"Nikolakopoulou","year":"2020","journal-title":"PLOS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12916-020-01880-8","article-title":"Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study","volume":"18","author":"Oikonomidi","year":"2020","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"779453","DOI":"10.3389\/fimmu.2021.779453","article-title":"Inflammation and platelet activation after COVID-19 vaccines \u2013 possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis","volume":"12","author":"Ostrowski","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyanv \u2013 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD015477-BIB0142|cit142","unstructured":"Oxford Vaccine Group Vaccine Knowledge Project: independent information about vaccines and infectious diseases vk.ovg.ox.ac.uk\/vk"},{"key":"10.1002\/14651858.CD015477-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015477-BIB0144|cit144","unstructured":"Pajon R Paila YD Girard B Dixon G Kacena K Baden LR Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial medRxiv 10.1101\/2021.09.28.21264252"},{"key":"10.1002\/14651858.CD015477-BIB0145|cit145","unstructured":"Pan HX Liu JK Huang BY Li GF Chang XY Liu YF Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (KCONVAC) in healthy adults: two randomized, double-blind, and placebo-controlled Phase 1\/2 clinical trials medRxiv 10.1101\/2021.04.07.21253850"},{"key":"10.1002\/14651858.CD015477-BIB0146|cit146","unstructured":"Pan HX Wu QH Zeng G Yang J Jiang DY Deng XW Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18\u201359 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial medRxiv 10.1101\/2021.07.23.21261026"},{"key":"10.1002\/14651858.CD015477-BIB0147|cit147","unstructured":"P\u00e9rez-Rodr\u00edguez S de la Caridad Rodr\u00edguez-Gonz\u00e1lez M Ochoa-Azze R Climent-Ruiz Y Alberto Gonz\u00e1lez-Delgado C Paredes-Moreno B A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity medRxiv 10.1101\/2021.10.04.21264522"},{"key":"10.1002\/14651858.CD015477-BIB0148|cit148","unstructured":"Pitisuttithum P Luvira V Lawpoolsri S Muangnoicharoen S Kamolratanakul S Sivakorn C Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, Phase 1\/2 trial medRxiv 10.1101\/2021.09.17.21263758"},{"issue":"27","key":"10.1002\/14651858.CD015477-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015477-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nature Reviews Immunology"},{"issue":"20","key":"10.1002\/14651858.CD015477-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.vaccine.2021.04.006","article-title":"The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18\u201359 years: a phase I randomized, double-blinded, controlled trial","volume":"39","author":"Pu","year":"2021","journal-title":"Vaccine"},{"issue":"10226","key":"10.1002\/14651858.CD015477-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(20)30365-2","article-title":"What are the risks of COVID-19 infection in pregnant women?","volume":"395","author":"Qiao","year":"2020","journal-title":"Lancet"},{"issue":"10267","key":"10.1002\/14651858.CD015477-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"issue":"10275","key":"10.1002\/14651858.CD015477-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomized, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD015477-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamacardio.2021.3444","article-title":"Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review","volume":"6","author":"Rizk","year":"2021","journal-title":"JAMA Cardiology"},{"key":"10.1002\/14651858.CD015477-BIB0157|cit157","unstructured":"Roozen GV Prins ML van Binnendijk R den Hartog G Kuiper VP Prins C Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy medRxiv 10.1101\/2021.07.27.21261116"},{"issue":"7","key":"10.1002\/14651858.CD015477-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we?","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Review of Vaccines"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","article-title":"Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis","volume":"11","author":"Rotshild","year":"2021","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1002\/14651858.CD015477-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromized host","volume":"58","author":"Rubin","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0161|cit161","unstructured":"Rucker G Schwarzer G R\u00fccker G Schwarzer G Krahn U K\u00f6nig J Network meta-analysis using frequentist methods \u2013 package netmeta cran.r\u2013project.org"},{"issue":"2","key":"10.1002\/14651858.CD015477-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15789\/2220-7619-ASB-1699","article-title":"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the \"EpiVacCorona\" vaccine for the prevention of COVID-19","volume":"11","author":"Ryzhikov","year":"2021","journal-title":"Russian Journal of Infection and Immunity"},{"key":"10.1002\/14651858.CD015477-BIB0163|cit163","unstructured":"Sadoff J Le Gars M Shukarev G Heerwegh D Truyers C de Groot AM Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial MedRxiv"},{"issue":"2","key":"10.1002\/14651858.CD015477-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015477-BIB0165|cit165","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD015477-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Sharifian-Dorche","year":"2021","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD015477-BIB0167|cit167","unstructured":"Shinde V Bhikha S Hoosain Z Archary M Bhorat Q Fairlie L for the 2019nCoV-501 Study Group Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant medRxiv"},{"issue":"16","key":"10.1002\/14651858.CD015477-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/CM9.0000000000001702","article-title":"Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial","volume":"134","author":"Shu","year":"2021","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD015477-BIB0169|cit169","unstructured":"Sridhar S Joaquin A Bonaparte MI Bueso A Chabanon AL Chen A Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study medRxiv 10.1101\/2021.10.08.21264302"},{"issue":"15","key":"10.1002\/14651858.CD015477-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S vaccine for COVID-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015477-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015477-BIB0172|cit172","unstructured":"Thomas SJ Moreira ED Kitchin N Absalon J Gurtman A Lockhart S Six month safety and efficacy of the BNT162b2 Mrna Covid-19 vaccine medRxiv"},{"issue":"3","key":"10.1002\/14651858.CD015477-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD015477-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"Riel","year":"2020","journal-title":"Nature Materials"},{"issue":"3","key":"10.1002\/14651858.CD015477-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"issue":"10277","key":"10.1002\/14651858.CD015477-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomized trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0177|cit177","unstructured":"Walsh EE Frenck R Falsey AR Kitchin N Absalon J Gurtman A RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study medRxiv"},{"issue":"6","key":"10.1002\/14651858.CD015477-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015477-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/sim.3008","article-title":"Allowing for uncertainty due to missing data in meta-analysis \u2013 part 1: two-stage methods","volume":"27","author":"White","year":"2008","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0180|cit180","unstructured":"World Health Organization Coronavirus disease 2019 (COVID-19). Situation report \u2013 51 apps.who.int\/iris\/handle\/10665\/331475"},{"key":"10.1002\/14651858.CD015477-BIB0181|cit181","unstructured":"World Health Organization Considerations for evaluation of COVID19 vaccines. Points to consider for manufacturers of COVID-19 vaccines. Version 24 September 2020 www.who.int\/docs\/default-source\/in-vitro-diagnostics\/covid19\/who-evaluation-covid-vaccine-w-lines.pdf?sfvrsn=701d3a65_2"},{"key":"10.1002\/14651858.CD015477-BIB0182|cit182","unstructured":"World Health Organization WHO target product profiles for COVID-19 vaccines. Version 3 \u2013 29 April 2020 www.who.int\/docs\/default-source\/blue-print\/who-target-product-profiles-for-covid-19-vaccines.pdf"},{"key":"10.1002\/14651858.CD015477-BIB0183|cit183","unstructured":"World Health Organization Tracking SARS-CoV-2 variants www.who.int\/activities\/tracking-SARS-CoV-2-variants"},{"key":"10.1002\/14651858.CD015477-BIB0184|cit184","unstructured":"World Health Organization COVID-19 vaccine tracker and landscape www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"10.1002\/14651858.CD015477-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1056\/NEJMp2033538","article-title":"Placebo-controlled trials of covid-19 vaccines \u2013 why we still need them","volume":"384","author":"WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015477-BIB0186|cit186","unstructured":"COVID-19 coronavirus pandemic www.worldometers.info\/coronavirus\/#countries"},{"issue":"12","key":"10.1002\/14651858.CD015477-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD015477-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD015477-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomized, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015477-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.eclinm.2021.101078","article-title":"A single-centre, randomized, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan","volume":"39","author":"Zakarya","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1002\/14651858.CD015477-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015477-BIB0193|cit193","unstructured":"Zeng B Gao L Zhou Q Yu K Sun F Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis medRxiv 10.1101\/2021.09.23.21264048"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/22221751.2021.1951126","article-title":"Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial","volume":"10","author":"Zhang","year":"2021","journal-title":"Emerging Microbes & Infections"},{"issue":"10249","key":"10.1002\/14651858.CD015477-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015477-BIB0196|cit196","doi-asserted-by":"crossref","unstructured":"Zhu F Jin P Zhu T Wang W Ye H Pan H Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomized, double-blind, placebo-controlled, phase 2b trial Clinical Infectious Diseases 2022 75 1 e783 91 10.1093\/cid\/ciab845","DOI":"10.1093\/cid\/ciab845"},{"issue":"1","key":"10.1002\/14651858.CD015477-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1093\/cid\/ciab845","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomized, double-blind, placebo-controlled, phase 2b trial","volume":"75","author":"Zhu","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015477-BIB0198|cit198","unstructured":"Grana C Ghosn L Boutron I Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis. PROSPERO 2021 CRD42021271897 www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=271897"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T02:32:00Z","timestamp":1717468320000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015477"}},"subtitle":[],"editor":[{"name":"Cochrane Emergency and Critical Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":198,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015477","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]}}}